Sylvester Launches MAC 3 to Tackle Kidney Cancer Through Metabolic Research and Diet
Sylvester Comprehensive Cancer Center shared on LinkedIn:
“Renal cell carcinoma, the most common type of kidney cancer, has distinct metabolic traits. To tackle this uniquely behaving cancer, a multidisciplinary team at Sylvester is taking an innovative approach.
Backed by a Sylvester Team Science Award, the researchers will study the cancer’s metabolism through detailed lab and clinical research. Their goal: to better understand these metabolic drivers and introduce a cutting-edge dietary intervention for patients.
Tracy Crane, is leading the new program, Metabolism And renal Cancer (MAC 3), along with Dr. David Lombard, co-leader of Sylvester’s Cancer Epigenetics Program and Dr. Scott Welford, co-leader of the Tumor Biology Program. The researchers will use a large database built by Dr. Jaime Merchan and his colleagues.
Through this collaborative project, Sylvester researchers will:
- Study the details of renal cell carcinoma lipids.
- Uncover how circadian clock genes may contribute to the disease.
- Analyze how body composition impacts response to treatment.
- Test intermittent fasting in a group of newly diagnosed patients.
Read about a historic first at Sylvester: a team of basic scientists, translational researchers and clinical experts uniting to lead high-quality research into the tumor metabolism of kidney cancer.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023